Progyny Posts Q2 EPS of 34c, Topping Expectations
PGNY sits 68% above its 52-week low of $16.1.
Summary
Progyny reported Q2 earnings per share of 34 cents, beating expectations, while revenue rose 5% and slightly exceeded estimates. The strong result builds on the 61% net income growth seen in Q1. The company had just completed a $200 million buyback in May, signaling management's confidence in the business. With the stock at $27.04, the market will now assess whether the full-year guidance remains on track.
At the time of this announcement, PGNY was trading at $27.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $16.10 to $33.07. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.